Improvement of preclinical animal models for autoimmune-mediated disorders via reverse translation of failed therapies

Boris Hart; Anwar Jagessar; Yolanda Kap; KG Haanstra; IHCHM Philippens; C Serguera; J Langermans; M Vierboom

doi:10.1016/j.drudis.2014.03.023

Improvement of preclinical animal models for autoimmune-mediated disorders via reverse translation of failed therapies

Boris Hart, Anwar Jagessar, Yolanda Kap, KG Haanstra, IHCHM Philippens, C Serguera, J Langermans, M Vierboom

Immunology

Research output: Contribution to journal › Article › Academic › peer-review

16 Citations (Scopus)

Abstract

The poor translational validity of autoimmune-mediated inflammatory disease (AIMID) models in inbred and specific pathogen-free (SPF) rodents underlies the high attrition of new treatments for the corresponding human disease. Experimental autoimmune encephalomyelitis (EAE) is a frequently used preclinical AIMID model. We discuss here how crucial information needed for the innovation of current preclinical models can be obtained from postclinical analysis of the nonhuman primate EAE model, highlighting the mechanistic reasons why some therapies fail and others succeed. These new insights can also help identify new targets for treatment.

Original language	Undefined/Unknown
Pages (from-to)	1394-1401
Number of pages	8
Journal	Drug Discovery Today
Volume	19
Issue number	9
DOIs	https://doi.org/10.1016/j.drudis.2014.03.023
Publication status	Published - 2014

Research programs

EMC MM-02-72-02

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.drudis.2014.03.023

http://hdl.handle.net/1765/60217

Cite this

@article{c4897c78c5d449538814e40f2f2a19ab,

title = "Improvement of preclinical animal models for autoimmune-mediated disorders via reverse translation of failed therapies",

abstract = "The poor translational validity of autoimmune-mediated inflammatory disease (AIMID) models in inbred and specific pathogen-free (SPF) rodents underlies the high attrition of new treatments for the corresponding human disease. Experimental autoimmune encephalomyelitis (EAE) is a frequently used preclinical AIMID model. We discuss here how crucial information needed for the innovation of current preclinical models can be obtained from postclinical analysis of the nonhuman primate EAE model, highlighting the mechanistic reasons why some therapies fail and others succeed. These new insights can also help identify new targets for treatment.",

author = "Boris Hart and Anwar Jagessar and Yolanda Kap and KG Haanstra and IHCHM Philippens and C Serguera and J Langermans and M Vierboom",

year = "2014",

doi = "10.1016/j.drudis.2014.03.023",

language = "Undefined/Unknown",

volume = "19",

pages = "1394--1401",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Ltd.",

number = "9",

}

TY - JOUR

T1 - Improvement of preclinical animal models for autoimmune-mediated disorders via reverse translation of failed therapies

AU - Hart, Boris

AU - Jagessar, Anwar

AU - Kap, Yolanda

AU - Haanstra, KG

AU - Philippens, IHCHM

AU - Serguera, C

AU - Langermans, J

AU - Vierboom, M

PY - 2014

Y1 - 2014

N2 - The poor translational validity of autoimmune-mediated inflammatory disease (AIMID) models in inbred and specific pathogen-free (SPF) rodents underlies the high attrition of new treatments for the corresponding human disease. Experimental autoimmune encephalomyelitis (EAE) is a frequently used preclinical AIMID model. We discuss here how crucial information needed for the innovation of current preclinical models can be obtained from postclinical analysis of the nonhuman primate EAE model, highlighting the mechanistic reasons why some therapies fail and others succeed. These new insights can also help identify new targets for treatment.

AB - The poor translational validity of autoimmune-mediated inflammatory disease (AIMID) models in inbred and specific pathogen-free (SPF) rodents underlies the high attrition of new treatments for the corresponding human disease. Experimental autoimmune encephalomyelitis (EAE) is a frequently used preclinical AIMID model. We discuss here how crucial information needed for the innovation of current preclinical models can be obtained from postclinical analysis of the nonhuman primate EAE model, highlighting the mechanistic reasons why some therapies fail and others succeed. These new insights can also help identify new targets for treatment.

U2 - 10.1016/j.drudis.2014.03.023

DO - 10.1016/j.drudis.2014.03.023

M3 - Article

C2 - 24704460

SN - 1359-6446

VL - 19

SP - 1394

EP - 1401

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 9

ER -